Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie

AI Briefing

• – Atopic Dermatitis treatment therapies are being developed by several companies, including GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, and Abbvie, with a focus on various mechanisms of action and routes of administration.
• – Clinical trials are ongoing to assess the efficacy and safety of these therapies, with DelveInsight's analysis highlighting key developments in the pipeline.
• – The Atopic Dermatitis pipeline is expected to grow significantly, with numerous companies working towards developing new treatments, driving innovation in the field.